Science
Naveen Pemmaraju
Naveen Pemmaraju/ youtube.com

Naveen Pemmaraju: Prognostic Impact of NPM1 Co-Mutation in FLT3-Mutated AML

Naveen Pemmaraju, Director of Leukemia-Cancer Network, Executive Director of Cancer Medicine, Director of BPDCN at the Department of Leukemia, and Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues published in Cancer:

“Important new paper led by Dr. Sankalp Arora and Naval Daver just out in ACS Journal Cancer.

FLT3TKD NPM1 for patients with AML.”

Title: Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation

Authors: Sankalp Arora, Wei-Ying Jen, Musa Yilmaz, Indraneel Deshmukh, Jayastu Senapati, Sanam Loghavi, Ghayas C. Issa, Nicholas J. Short, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Joseph Jabbour, Naveen Pemmaraju, Michael Andreeff, Koichi Takahashi, Kapil Bhalla, Uday Popat, Elizabeth J. Shpall, Betul Oran, Hussein A. Abbas, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Naval Daver

You can read the Full Article on Cancer.

Naveen Pemmaraju: Prognostic Impact of NPM1 Co-Mutation in FLT3-Mutated AML

More posts featuring Naveen Pemmaraju.

Acute Myeloid Leukemia AML Betül Oran cancer Courtney D. DiNardo Elizabeth J. Shpall Farhad Ravandi Gautam Borthakur Ghayas C. Issa Guillermo Garcia-Manero Hagop Kantarjian Hussein A. Abbas Indraneel Deshmukh Jayastu Senapati Joseph Jabbour Kapil Bhalla Koichi Takahashi Michael Andreeff Musa Yilmaz Naval Daver Naveen Pemmaraju Nicholas J. Short OncoDaily Oncology Sanam Loghavi Sankalp Arora Tapan M. Kadia Uday Popat Wei Ying Jen